Korro Bio submits to Australian ethics committee to begin Phase 1/2 trial for KRRO-121 in UCDs

Korro Bio, Inc.

Submission to Alfred Health Human Ethics Committee to start first-in-human Phase 1/2 trial of KRRO-121.
KRRO-121 is a GalNAc-conjugated RNA editing oligonucleotide targeting hyperammonemia in Urea Cycle Disorders.
Trial will evaluate safety, tolerability of escalating doses, and pharmacokinetics in healthy volunteers and UCD patients.
Listed on ClinicalTrials.gov as NCT07773246.
No clinical data released yet; first-in-human milestone for the program.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.